目的:观察新辅助化疗配合手术治疗中晚期乳腺癌的临床效果,为临床研究提供参考。方法:选取我院2009年5月-2011年4月收治的中晚期乳腺癌患者107例,根据治疗方法的不同,将患者分为新辅助化疗组和对照组。新辅助化疗组采取术前辅助化疗,而对照组术前不接受化疗。观察新辅助化疗组患者的近期临床疗效、毒副反应发生率;比较两组患者的手术时间、术中出血量等;术后随访三年,记录两组患者的肿瘤局部复发率及远处转移率。结果:新辅助化疗组患者治疗的总有效率为79.66%,毒副反应的发生率为33.89%;新辅助化疗组的平均手术时间、术中出血量均低于对照组,差异具有统计学意义(P<0.05)。新辅助化疗组患者的局部复发率为5.08%,远处转移率为6.78%;对照组患者局部复发率为12.50%,远处转移率为18.75%。新辅助化疗组患者的肿瘤复发转移率低于对照组,差异具有统计学意义(P<0.05)。结论:在中晚期乳腺癌的临床治疗中,术前对患者实施新辅助化疗具有明显的效果,患者近期疗效良好,毒副反应可耐受,且手术后的复发转移率相对较低,值得推广应用。 Objective: To observe the clinical effect of neoadjuvant chemotherapy in the treatment of advanced breast cancer and provide a reference for clinical research. Methods: A total of 107 patients with advanced breast cancer who were treated in our hospital from May 2009 to April 2011 were selected. According to the different treatment methods, the patients were divided into neoadjuvant chemotherapy group and control group. Neoadjuvant chemotherapy group preoperative adjuvant chemotherapy, while the control group did not receive chemotherapy before surgery. To observe the recent clinical efficacy and the incidence of toxic and side effects in patients receiving neoadjuvant chemotherapy. The operation time and blood loss were compared between the two groups. After three years of follow-up, the local recurrence rate and distant metastasis rate. Results: The total effective rate of neoadjuvant chemotherapy group was 79.66% and the incidence of toxic and side reaction was 33.89%. The average operation time and intraoperative blood loss of neoadjuvant chemotherapy group were lower than that of control group, the difference was statistically significant (P <0.05). The neoadjuvant chemotherapy group had a local recurrence rate of 5.08% and distant metastasis rate of 6.78%. The control group had a local recurrence rate of 12.50% and distant metastasis rate of 18.75%. Neoadjuvant chemotherapy group of patients with tumor recurrence and metastasis rate was lower than the control group, the difference was statistically significant (P <0.05). Conclusion: In the clinical treatment of advanced breast cancer, preoperative neoadjuvant chemotherapy in patients with significant effect, the recent good effect, side effects can be tolerated, and the recurrence and metastasis after surgery is relatively low, it is worth promoting application.